Evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer remains on track to report topline Phase 2 ASPEN-09 data in mid-2027 from 80 patients. The update is progress-oriented but provides no efficacy/safety results yet, suggesting limited near-term price impact.
Evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer remains on track to report topline Phase 2 ASPEN-09 data in mid-2027 from 80 patients. The update is progress-oriented but provides no efficacy/safety results yet, suggesting limited near-term price impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
